Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
FactSet Research Systems enters the new quarter with its short base still elevated near 10% of free float, while options hedging continues to unwind from the defensive extreme that preceded last week's earnings print.
The short position has barely budged since the previous note. SI edged down fractionally to 3.73 million shares, representing 9.96% of free float, compared to 9.9% at the time of the September 30 article. The covering wave that followed the September 24 earnings print, which squeezed shorts from roughly 11.7% down to near 10%, has effectively stalled. A small rebuild was visible mid-week before another tick lower on Wednesday. At this level, the short base remains one of the larger structural positions in the financial data sector. Borrowing costs remain negligible at 0.54%, and availability has actually loosened from 234% to 264%, meaning there are now more than two and a half shares available to lend for every share already short. The lending market is under no stress. Shorts are staying put by conviction, not inertia.
The more interesting shift is in options. The put/call ratio has dropped to 1.83, well below the 20-day mean of 2.51 and roughly 1.45 standard deviations below it. For context, the ratio touched 3.24 at its 52-week peak in September, driven by aggressive put-buying ahead of results. That hedging has now been stripped out. The current reading is closer to the cautious-neutral zone than the defensive extreme of a month ago. Options traders are no longer pricing for a calamity, though the PCR remains above 1, so the bias is still modestly toward puts.
The Street is broadly neutral but lifting targets. Following the September 24 print, Wells Fargo and Stifel both raised their targets to $250 and $292 respectively on October 1, while maintaining Underweight and Hold ratings. That pattern, targets going up, ratings staying cautious, has been consistent across the coverage universe over the past month. Morgan Stanley raised to $300 from $230 in September while holding Equal-Weight. Barclays and Deutsche Bank made similar moves. The mean target of $278 sits only modestly above the current price of $272.78, leaving limited implied upside from consensus. Factor scores tell a bifurcated story: EPS momentum ranks in the 96th percentile over 30 days and the 87th over 90 days, forward earnings estimates are rising sharply, and the analyst recommendation differential ranks in the 91st percentile. Against that, the short score rank sits in the 11th percentile, meaning the stock screens as one of the more shorted names in its universe, and the valuation score on EV/EBIT is in the 43rd percentile, roughly mid-table.
The bull and bear cases are clearly drawn. Bulls point to AI monetisation gaining traction, with around 10% of net new ASV in the most recent quarter tied to AI solutions and API call volumes up 13-fold quarter-on-quarter. Bears flag margin pressure from 250 basis points of growth investment, elongated sales cycles, and pricing competition from Bloomberg, S&P CapIQ, and MSCI. On the stock's one-month chart, the 10% decline tells the bear case more than the 1% weekly bounce tells the bull case.
Baron Capital remains the largest disclosed holder at 11.81% of shares, and its position grew by 444,000 shares in the period to June 30. No 13D activist is on the register. AQR added 1.36 million shares in the same period, the largest incremental build among the top holders, though that data is as of June. All Schedule 13D/G stakes are as last disclosed, and holders can drop below 5% without filing again.
The next earnings date is November 10. With the post-results short-covering wave now exhausted and SI stabilising near 10% of float, what to watch is whether the short base begins a fresh rebuild into that print, or whether the easing options skew signals that conviction on the bear side is genuinely fading.
See the live data behind this article on ORTEX.
Open FDS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
